Biomimetic Nanomaterials for the Immunomodulation of the Cardiosplenic Axis Postmyocardial Infarction

The spleen is an important mediator of both adaptive and innate immunity. As such, attempts to modulate the immune response provided by the spleen may be conducive to improved outcomes for numerous diseases throughout the body. Here, biomimicry is used to rationally design nanomaterials capable of splenic retention and immunomodulation for the treatment of disease in a distant organ, the postinfarct heart. Engineered senescent erythrocyte-derived nanotheranostic (eSENTs) are generated, demonstrating significant uptake by the immune cells of the spleen including T and B cells, as well as monocytes and macrophages. When loaded with suberoylanilide hydroxamic acid (SAHA), the nanoagents exhibit a potent therapeutic effect, reducing infarct size by 14% at 72 h postmyocardial infarction when given as a single intravenous dose 2 h after injury. These results are supportive of the hypothesis that RBC-derived biomimicry may provide new approaches for the targeted modulation of the pathological processes involved in myocardial infarction, thus further experiments to decisively confirm the mechanisms of action are currently underway. This novel concept may have far-reaching applicability for the treatment of a number of both acute and chronic conditions where the immune responses are either stimulated or suppressed by the splenic (auto)immune milieu. Biomimetic hybrid nanotheranostics are generated featuring an engineered senescent erythrocyte-based coating material. These nanoagents demonstrate innate localization to the spleen, similar to the source material, and when combined with the histone deacetylase inhibitor suberoylanilide hydroxamic acid, elicit an immunomodulatory effect capable of reducing infarct size in the heart after myocardial infarction.image

Automated summary

This study demonstrates the potential of biomimetic nanomaterials for modulating immune response and improving outcomes in heart diseases. The engineered senescent erythrocyte-derived nanotheranostics (eSENTs) showed significant uptake in immune cells and exhibited a therapeutic effect in reducing infarct size.